跳至主要内容
临床试验/CTRI/2011/091/000054
CTRI/2011/091/000054已完成4 期

Assessment of efficacy and safety of ?Triglow? Cream (Combination of Hydroquinone 2%, Tretinoin 0.05% and Fluocinolone acetonide 0.01%) in the treatment of Facial Melasma.

Glenmark Pharmaceutical Ltd0 个研究点目标入组 90 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • ?Subjects with facial Melasma and not used any topical treatments for Melasma for 2 weeks prior to enrollment in study.
  • ?Subjects must be 18 and above.
  • ?Subjects must provide written informed consent and comply to the protocol

排除标准

  • ?Subjects who had used any topical treatment for Melasma for 2 weeks prior to enrollment in study.
  • ?Subjects under treatment for a dermatologic condition, which may interfere with the safe evaluation of the study combination (e.g. eczema, psoriasis, severe sun-damage, dermatitis)
  • ?Hypersensitivity to any ingredients of Triglow
  • ?Subjects who have undergone any surgical treatment of the face.
  • ?Subjects with a diagnosis of skin cancer in the areas to be treated.

研究者

发起方
Glenmark Pharmaceutical Ltd

相似试验

A clinical trial to study the effect of triple... | 临床试验